Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Herbalife (NYSE: HLF) were looking unhealthy today, falling 10% after a U.S. lawmaker called for an investigation into the multilevel marketing company.
So what: This morning, Senator Edward Markey (D-Mass.) leveled a familiar accusation at the health-supplement supplier, calling it a "possible pyramid scheme." His office said in a press release that Markey had received complaints from constituents about "improper pressure and financial hardship" related to the company's dealings. Markey said he sent letters to the SEC and Federal Trade Commission, as well as to Herbalife itself, in an effort to get more information on the company.
Now what: This is far from the first time the "pyramid scheme" charge has been lobbed at Herbalife. Hedge fund manager Bill Ackman similarly lambasted the company a year ago in a blistering short thesis, and peer Nu Skin Enterprises was also called a pyramid scheme by an official Chinese newspaper last week. A Herbalife spokesman said the company received the letter and looks "forward to an opportunity to introduce the company to him and address his concerns at his earliest convenience." Shares have bounced back strongly from Ackman's charges a year ago as Carl Icahn took to the company's defense, but this is clearly a battleground stock. Any investors hopping on for a ride should expect it to be bumpy.
What's hot in biotech?
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.